NCT06144424

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Escient Pharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Oral EP262	Once daily
DRUG	Placebo	Once Daily

Timeline

• Start date: 2023-10-25
• Primary completion: 2024-07-31
• Completion: 2024-07-31
• First posted: 2023-11-22
• Last updated: 2025-08-24
• Results posted: 2025-08-24

Locations

10 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study